Tectonic Therapeutic Inc. (TECX)
TECX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TECX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001681087 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NY |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated fin" | 10-Q 2026-11-05 |
| Cash and burn | $234.7M cash; operating cash flow -$17.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 19,948,037 (2026-10-30); 18,716,280 a year earlier; 44,573,911 three years earlier. 3y figure adjusted for split (1-for-12 overall). | Cover page 2026-10-30 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2024-06-21 | Source 2024-06-21 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $182K, sold $639K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$21.3M | -$14.9M | $234.7M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$22.3M | -$21.5M | $227.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$25.2M | -$18.4M | $236.9M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$19.2M | -$14.5M | $253.8M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | Not filed | -$19.0M | -$17.8M | $268.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$20.0M | -$14.7M | $287.4M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$15.9M | -$13.1M | $306.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$12.4M | -$16.8M | $141.2M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-07-15 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 582 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.4% |
| 1 month | -0.8% |
| 3 months | -37.8% |
| Year to date | +1.3% |
| 1 year | +20.3% |
| From 52-week high | -44.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TVGN | Tevogen Inc. | $6.22 | +3.67% | $422.2M |
| IRLA | IRulya Therapeutics Inc. | $37.36 | -6.13% | $405.0M |
| SLBT | SL Science Holding Limited | $0.7195 | -3.42% | $403.5M |
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| ALEC | Alector Inc. | $2.57 | +1.18% | $382.6M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
| CCCC | C4 Therapeutics Inc. | $2.65 | -3.99% | $348.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier